These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38554546)

  • 1. A pragmatic guide for management of adverse events associated with lorlatinib.
    Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
    Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
    Igawa Y; Yoshida T; Makihara R; Torasawa M; Tateishi A; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    Lung Cancer; 2024 Oct; 196():107954. PubMed ID: 39303401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
    Arriola E; de Castro J; García-Campelo R; Bernárdez B; Bernabé R; Bruna J; Dómine M; Isla D; Juan-Vidal Ó; López-Fernández T; Nadal E; Rodríguez-Abreu D; Vares M; Asensio Ú; García LF; Felip E
    Clin Drug Investig; 2024 Aug; 44(8):553-576. PubMed ID: 39085682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Shih JY; Luo YH; Chang GC; Chang JW; Wang CC; Yang TY; Fang WT; Shau WY
    J Formos Med Assoc; 2024 Aug; 123(8):875-881. PubMed ID: 38195317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
    Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
    Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Lorlatinib or Crizotinib in Advanced
    Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
    N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical properties of lorlatinib in the treatment of
    El Darsa H; Abdel-Rahman O; Sangha R
    Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
    Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
    Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
    Reed M; Rosales AS; Chioda MD; Parker L; Devgan G; Kettle J
    Adv Ther; 2020 Jun; 37(6):3019-3030. PubMed ID: 32399810
    [TBL] [